A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Public ClinicalTrials.gov record NCT06065540. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).
Study identification
- NCT ID
- NCT06065540
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,734 participants
Conditions and interventions
Conditions
Interventions
- Cagrilintide Drug
- Semaglutide Drug
- Placebo cagrilintide Drug
- Placebo semaglutide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 26, 2023
- Primary completion
- Nov 18, 2025
- Completion
- Jan 5, 2026
- Last update posted
- Jul 7, 2026
2023 – 2026
United States locations
- U.S. sites
- 100
- U.S. states
- 30
- U.S. cities
- 82
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Synexus Clin Res-Birmingham | Birmingham | Alabama | 35211 | — |
| Univ of Alabama_Birmingham | Birmingham | Alabama | 35294 | — |
| Cahaba Research | Pelham | Alabama | 35124 | — |
| Velocity Clinical Research-Phoenix | Phoenix | Arizona | 85006 | — |
| Synexus Rsch /Cnt Phnx Med C | Phoenix | Arizona | 85020 | — |
| Arkansas Clinical Research | Little Rock | Arkansas | 72205 | — |
| Velocity Clinical Res-Banning | Banning | California | 92220 | — |
| Velocity Clin Res-Chula Vista | Chula Vista | California | 91911 | — |
| John Muir Physicians Network | Concord | California | 94520 | — |
| Headlands Research California, LLC | Escondido | California | 92025 | — |
| Velocity Clin Res Gardena | Gardena | California | 90247 | — |
| Velocity Clin Res San Diego | La Mesa | California | 91942 | — |
| Loma Linda Univ Hlth Cr Endo | Loma Linda | California | 92354 | — |
| Facey Medical Foundation | Mission Hills | California | 91345 | — |
| Desert Oasis Hlthcr Med Group | Palm Springs | California | 92262 | — |
| Velocity Clin Res- San Bern | San Bernardino | California | 92408 | — |
| Linda Vista Health Care Ctr | San Diego | California | 92111 | — |
| Velocity Clin Res Santa Ana | Santa Ana | California | 92704 | — |
| Premier Medical Center, Inc. | Toluca Lake | California | 91602 | — |
| Velocity Clin Res - Panorama | Van Nuys | California | 91405 | — |
| Optumcare Clinical Trials,LLC-Golden | Colorado Springs | Colorado | 80906 | — |
| Northeast Research Institute | Jacksonville | Florida | 32204 | — |
| Clinical Trial Services Corp | Miami | Florida | 33144 | — |
| Bioclinical Research Alliance | Miami | Florida | 33155 | — |
| New Horizon Research Center | Miami | Florida | 33165 | — |
| South Broward Research LLC | Miramar | Florida | 33027 | — |
| West Orange Endocrinology | Ocoee | Florida | 34761 | — |
| Optimal Research Sites | Orange City | Florida | 32763 | — |
| Advent Health-Res Inst | Orlando | Florida | 32804 | — |
| AdventHealth Diab Inst | Orlando | Florida | 32804 | — |
| Synexus Clin Res - Orlando | Orlando | Florida | 32806 | — |
| Oviedo Medical Research, LLC | Oviedo | Florida | 32765 | — |
| Hope Clin Res & Wellness | Conyers | Georgia | 30094 | — |
| East Coast Institute for Res | Macon | Georgia | 31210 | — |
| Urban Family Practice Assoc | Marietta | Georgia | 30067 | — |
| Endocrine Research Solutions, Inc. | Roswell | Georgia | 30076 | — |
| Endocrine Research Solutions | Roswell | Georgia | 30076 | — |
| Pacific Diabetes & Endo Ctr | Honolulu | Hawaii | 96813 | — |
| St. Luke's Health System | Boise | Idaho | 83702 | — |
| Solaris Clinical Research | Meridian | Idaho | 83646 | — |
| Cedar-Crosse Research Center | Chicago | Illinois | 60607 | — |
| Clinical Invest Special_Gurnee | Gurnee | Illinois | 60031 | — |
| Endeavor Health | Skokie | Illinois | 60077 | — |
| Evanston Premier Hlthcr Res | Skokie | Illinois | 60077 | — |
| Iowa Diabetes & Endo Res Ctr | West Des Moines | Iowa | 50266 | — |
| Alliance for Multispec Res | Newton | Kansas | 67114 | — |
| Cotton-O'Neil Diab & Endo Ctr | Topeka | Kansas | 66606 | — |
| Velocity Clin Res Lafayette | Lafayette | Louisiana | 70508 | — |
| BTC of New Bedford, LLC | New Bedford | Massachusetts | 02740 | — |
| Velocity Clin Res Gulfport | Gulfport | Mississippi | 39503 | — |
| Diabetes & Endo Specialists Inc | Chesterfield | Missouri | 63017 | — |
| Premier Research Inc. | Trenton | New Jersey | 08611 | — |
| Velocity Clin Res Albuquerque | Albuquerque | New Mexico | 87107 | — |
| AMC Community Endocrinology | Albany | New York | 12203 | — |
| Velocity Clin Res Syracuse | East Syracuse | New York | 13057 | — |
| Southgate Medical Group, LLP | West Seneca | New York | 14224 | — |
| Great Lakes Medical Research | Westfield | New York | 14787 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | — |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | 27408 | — |
| Carteret Medical Group | Morehead City | North Carolina | 28557 | — |
| Piedmont Healthcare/Research | Statesville | North Carolina | 28625 | — |
| Accellacare | Wilmington | North Carolina | 28401 | — |
| Synexus Clinical Research US, Inc | Akron | Ohio | 44311 | — |
| Centricity Research | Columbus | Ohio | 43213 | — |
| Alliance for Multispec Res | Norman | Oklahoma | 73069 | — |
| Clinical Res Collaborative | Cumberland | Rhode Island | 02864 | — |
| Velocity Clin Res Providence | East Greenwich | Rhode Island | 02818 | — |
| AnMed Health IMA | Anderson | South Carolina | 29621 | — |
| Synexus Clin Res US-Anderson | Anderson | South Carolina | 29621 | — |
| Velocity Clinical Res-Anderson | Anderson | South Carolina | 29621 | — |
| Velocity Clin Res Gaffney | Gaffney | South Carolina | 29340 | — |
| Hillcrest Clinical Research | Simpsonville | South Carolina | 29681-1538 | — |
| Spartanburg Medical Research | Spartanburg | South Carolina | 29303 | — |
| Velocity Clin Res Spartanburg | Spartanburg | South Carolina | 29303 | — |
| Holston Medical Group Pc | Bristol | Tennessee | 37620-7352 | — |
| Holston Medical Group | Kingsport | Tennessee | 37660 | — |
| Clinical Research Associates | Nashville | Tennessee | 37203 | — |
| Arlington Family Res. Ctr Inc | Arlington | Texas | 76012-4637 | — |
| Velocity Clin Res Austin | Austin | Texas | 78759 | — |
| UT Health University of Texas | Bellaire | Texas | 77401 | — |
| Velocity Clinical Res-Dallas | Dallas | Texas | 75230 | — |
| North Texas Endocrine Center | Dallas | Texas | 75231 | — |
| Synexus Clin Res Dallas | Dallas | Texas | 75234 | — |
| Cedar Health Research | Dallas | Texas | 75251 | — |
| JCCT- Juno NW Houston | Houston | Texas | 77040 | — |
| Synergy Groups Medical | Houston | Texas | 77061 | — |
| PlanIt Research, PLLC | Houston | Texas | 77079 | — |
| Medical Colleagues-Texas LLP | Katy | Texas | 77450 | — |
| Sante Clinical Research | Kerrville | Texas | 78028 | — |
| Discovery MM Services, INC Missouri | Missouri City | Texas | 77459 | — |
| AES San Antonio | San Antonio | Texas | 78229 | — |
| University of Texas San Antonio | San Antonio | Texas | 78229 | — |
| NE Clin Res of San Antonio | San Antonio | Texas | 78233 | — |
| Consano Clinical Research, LLC | Shavano Park | Texas | 78231 | — |
| DM Clin Rsrch/Fam Diag Clinic | Tomball | Texas | 77375 | — |
| Diabetes & Endo Treatment Spec | Sandy City | Utah | 84093 | — |
| Velocity Clin Res-Salt Lk City | West Jordan | Utah | 84088 | — |
| TPMG Clinical Research | Newport News | Virginia | 23606 | — |
| Rainier Clin Res Ctr Inc | Renton | Washington | 98057 | — |
| St. Vincent Hosp-Prevea Health | Green Bay | Wisconsin | 54303 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 305 non-U.S. sites.
Recently updated Type 2 Diabetes Mellitus trials
Other public records listing Type 2 Diabetes Mellitus. Sorted by last update posted; newest first. Not a recommendation.
- NCT07743450: A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes Recruiting
- NCT07662044: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus Recruiting
- NCT07521475: Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes Recruiting
- NCT07662135: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin Recruiting
- NCT07662109: A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus Recruiting
- NCT07662213: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06065540, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06065540 live on ClinicalTrials.gov.